Page 150 - 17_Atti_SNO_2023_flip

Proceedings SNO “LXII Congresso Nazionale SNO”

tori, di solfato di magnesio, di deferoxamina ed il blocco 4. Otite F, Mink S, Tan CO, Puri A, Zamani AA, Mehregan A,
dei gangli neurali (7,10) ; l’uso del milrinone intrarterioso ed Chou S, Orzell S, Purkayastha S, Du R, Sorond FA. Impaired
(8)
endovenoso è un’opzione nel vasospasmo refrattario . cerebral autoregulation is associated with vasospasm and de-
❒ ❒ CONCLUSIONI. L’eziologia multifattoriale del vasospa- layed cerebral ischemia in subarachnoid hemorrhage. Stroke
2014; 45 (3): 677-682.
smo e della DCI, conseguenze di fenomeni di neuroin-
fiammazione, microtrombosi e depolarizzazione della 5. Francoeur CL, Mayer SA. Management of delayed cerebral
membrana endoteliale, richiede necessariamente una valu- ischemia after subarachnoid hemorrhage. Crit Care 2016; 20
(1): 277.
tazione ed una diagnosi multimodale di tali condizioni pa-
tologiche finalizzata all’applicazione di nuove strategie te- 6. Gathier CS, Dankbaar JW, van der Jagt M, Verweij BH,
rapeutiche a sostegno del consolidato trattamento farmaco- Oldenbeuving AW, Rinkel GJ, van den Bergh WM, Slooter
logico noto. AJ; HIMALAIA Study Group. Effects of induced hyperten-
sion on cerebral perfusion in delayed cerebral ischemia after
aneurysmal subarachnoid hemorrhage: a randomized clinical
trial. Stroke 2015; 46 (11): 3277-3281.
BIBLIOGRAFIA
7. Torregrossa F, Grasso G. Therapeutic approaches for cere-
1. Hoh BL, Ko NU, Amin-Hanjani S, Chou SH-Y, Cruz-Flores S,
brovascular dysfunction after aneurysmal subarachnoid hem-
Dangayach NS, Derdeyn CP, Du R, Hänggi D, Hetts SW, orrhage: an update and future rerspectives. World Neurosurg
Ifejika NL, Johnson R, Keigher KM, Leslie-Mazwi TM, Lucke- 2022; 159: 276-287.
Wold B, Rabinstein AA, Robicsek SA, Stapleton CJ, Suarez JI,
Tjoumakaris SI, Welch BG. 2023 Guideline for the manage- 8. respy T, Heintzelmann M, Chiron C, Vinclair M, Tahon F,
ment of patients with aneurysmal subarachnoid hemorrhage: a Francony G, Payen JF. Which protocol for milrinone to treat
guideline from the American Heart Association/American cerebral vasospasm associated with subarachnoid hemor-
Stroke Association. Stroke 2023; 54 (7): e314-e370. rhage? J Neurosurg Anesthesiol 2019; 31 (3): 323-329.
2. Treggiari MM, Rabinstein AA, Busl KM, Caylor MM, Citerio 9. Reddy D, Fallah A, Petropoulos JA, Farrokhyar F, Macdonald
G, Deem S, Diringer M, Fox E, Livesay S, Sheth KN, Suarez RL, Jichici D. Prophylactic magnesium sulfate for aneurysmal
JI, Tjoumakaris S. Guidelines for the neurocritical care man- subarachnoid hemorrhage: a systematic review and meta-
agement of aneurysmal subarachnoid hemorrhage. Neurocrit analysis. Neurocrit Care 2014; 21 (2): 356-364.
Care 2023; 39 (1): 1-28. 10. Hänggi D, Etminan N, Macdonald RL, Steiger HJ, Mayer SA,
3. Rowland MJ, Hadjipavlou G, Kelly M, Westbrook J, Pattinson Aldrich F, Diringer MN, Hoh BL, Mocco J, Strange P, Faleck
KT. Delayed cerebral ischaemia after subarachnoid haemor- HJ, Miller M. NEWTON: Nimodipine microparticles to en-
rhage: looking beyond vasospasm. Br J Anaesth 2012; 109 hance recovery while reducing toxicity after subarachnoid
(3): 315-329. hemorrhage. Neurocrit Care 2015; 23 (2): 274-284.

- 148 -